MeiraGTx Holdings plc Ordinary Shares MGTX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T15:34:00.911Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:33:11.016298452Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T15:32:49.455442+00:00
MeiraGTx Holdings plc Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 7.69 | 492.3% | 38.6% | |||
| 30Δ | 8.47 | 460.2% | 33.4% | |||
| 35Δ | 9.24 | 428.1% | 28.2% | |||
| 40Δ | 10.01 | 396.1% | 23.0% | |||
| 45Δ | 10.41 | 368.0% | 20.1% | |||
| 50Δ | 10.81 | 339.9% | 17.3% | |||
| 55Δ | 10.84 | 400.4% | 33.4% | 11.21 | 311.7% | 14.4% |
| 60Δ | 10.18 | 422.1% | 30.0% | 11.61 | 283.6% | 11.6% |
| 65Δ | 12.01 | 255.5% | 8.7% | |||
| 70Δ | 12.40 | 227.4% | 5.9% | |||
| 75Δ | 13.00 | 214.6% | 4.4% | |||
| 80Δ | 13.65 | 206.7% | 3.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.69
- IV
- 492.3%
- B/E move
- 38.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.47
- IV
- 460.2%
- B/E move
- 33.4%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.24
- IV
- 428.1%
- B/E move
- 28.2%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.01
- IV
- 396.1%
- B/E move
- 23.0%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.41
- IV
- 368.0%
- B/E move
- 20.1%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.81
- IV
- 339.9%
- B/E move
- 17.3%
55Δ
- Pseudo strike
- 10.84
- IV
- 400.4%
- B/E move
- 33.4%
- Pseudo strike
- 11.21
- IV
- 311.7%
- B/E move
- 14.4%
60Δ
- Pseudo strike
- 10.18
- IV
- 422.1%
- B/E move
- 30.0%
- Pseudo strike
- 11.61
- IV
- 283.6%
- B/E move
- 11.6%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.01
- IV
- 255.5%
- B/E move
- 8.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.40
- IV
- 227.4%
- B/E move
- 5.9%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.00
- IV
- 214.6%
- B/E move
- 4.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.65
- IV
- 206.7%
- B/E move
- 3.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 191.07% | |
| 185.81% | |
| 186.23% | |
| 190.71% | |
| 208.29% | |
| 188.19% | |
| 191.28% | |
| 181.13% | |
| 215.25% | |
| 222.26% |
Biotechnology
MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver…
More →MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular drugs. The company is headquartered in Montral,…
More →MLTX
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug delivery…
More →MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The…
More →MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United…
More →MPLT
MapLight Therapeutics, Inc. is an innovative biotechnology company that is dedicated to developing groundbreaking therapies for complex neurological and psychiatric disorders.…
More →